Equities research analysts predict that argenx SE – (NASDAQ:ARGX) will announce sales of $6.35 million for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for argenx’s earnings. The lowest sales estimate is $2.80 million and the highest is $9.28 million. The firm is expected to report its next earnings results before the market opens on Thursday, August 2nd.
On average, analysts expect that argenx will report full year sales of $27.13 million for the current fiscal year, with estimates ranging from $16.58 million to $36.31 million. For the next year, analysts anticipate that the company will report sales of $24.68 million per share, with estimates ranging from $12.23 million to $37.12 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for argenx.
Several research firms have weighed in on ARGX. SunTrust Banks began coverage on argenx in a research report on Sunday, April 8th. They set a “buy” rating and a $125.00 price objective on the stock. Wedbush lifted their price objective on argenx from $93.00 to $114.00 and gave the company an “outperform” rating in a research report on Monday, June 25th. ValuEngine raised argenx from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $130.00 price objective on shares of argenx in a research report on Thursday, June 7th. Finally, JMP Securities lifted their target price on shares of argenx from $93.00 to $130.00 and gave the company a “positive” rating in a report on Monday, June 18th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $122.83.
argenx traded down $0.20, hitting $91.93, during trading hours on Friday, Marketbeat Ratings reports. 72,300 shares of the stock traded hands, compared to its average volume of 145,418. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of -65.66 and a beta of 2.44. argenx has a one year low of $19.81 and a one year high of $103.00.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Further Reading: Understanding Average Daily Trade Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.